The current earnings forecast score of argenx SE is 8.54, ranking 110 out of 387 in the Biotechnology & Medical Research industry. The average price target is 925.00, with a high of 1124.00 and a low of 715.00.

Analyst Rating

Based on 28 analysts

Buy

Current Rating

1083.772

Target Price

+27.31%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

497

Total

Median

Average

Company name

Ratings

Analysts

argenx SE

ARGX

Beigene Ltd

ONC

Ionis Pharmaceuticals Inc

IONS

IQVIA Holdings Inc

IQV

Insmed Inc

INSM

Kymera Therapeutics Inc

KYMR

...

100

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Forecast

Actual

FAQs

What is argenx SE's expected revenue for the next quarter?



argenx SE's expected revenue is 1.65B.

What is argenx SE's price target?



Analysts forecast that argenx SE's price target is USD 925.00, with the highest forecast at USD 1.12K and the lowest forecast at USD 715.00.

How have argenx SEARGX's recent earnings per share performed?



The market expectation was USD 7.57, while argenx SEARGX's earnings per share (EPS) for the previous quarter was USD 5.90. EPS for the next quarter is expected at USD 7.48.

What is the analyst rating for argenx SE?



Based on the ratings of argenx SE's stock from 28 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.